Skip to main content
OpenTrials
Completed

NCT Number: NCT05000593

Clinical Study of Cord Blood Mononuclear Cells (UCB-MNCs) in the Treatment of Knee Osteoarthritis

Umbilical cord blood mononuclear cells contain hematopoietic stem cells (HSC), mesenchymal stem cells (MSC), endothelial progenitor cells and other pluripotent stem cells, as well as immature immune cells, which can differentiate into chondrocytes, hematopoietic, epithelial, endothelial and nerve cells. It gives the ability to promote wound healing and vascular microcirculation reconstruction, and has the potential to treat many diseasesHowever, clinical studies on cord blood mononuclear cells in knee osteoarthritis have not been reported in the literature. Therefore, this study aims to explore the safety and effectiveness of cord blood mononuclear cells in the treatment of patients with knee osteoarthritis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Knee Osteoarthritis Arthritis Joint Diseases Musculoskeletal Diseases Osteoarthritis Osteoarthritis, Knee Rheumatic Diseases

Age range

30 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Qianfoshan Hospital

Jinan, Shandong, 252000, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥30 years old, ≤75 years old, no gender limit;
  • Meet the KOA diagnostic criteria in the "Classification Criteria for Knee Osteoarthritis" revised by the American College of Rheumatology (ACR);
  • According to the X-ray K-L grading and evaluation standard, it is at level II-III;
  • Continuous pain for at least 6 months;
  • No local or systemic infection;
  • There is no obvious contraindication for articular cavity puncture in hematology and biochemical testing;
  • Subjects and their families understand the clinical trial protocol and agree to participate in the trial, voluntarily and sign an informed consent form;

Exclusion criteria

  • Age<30 years old;
  • Tumor diseases;
  • Severe kidney, lung or liver damage;
  • Blood diseases include anemia and thrombocytopenia;
  • Type I diabetes;
  • Severe effusion;
  • Contracture or instability of the knee joint, with an axial deformity greater than 10°;
  • Infectious arthritis or skin disease;
  • Inject corticosteroids and immunosuppressants into the knee joint within 2 months;
  • Suffer from mental illness and poor compliance;
  • Cases that the investigator thinks are not suitable for inclusion in the group.

Treatment and study plan

Normal Saline

Other

Intra-articular injection of normal saline

Cord Blood Mononuclear Cells (UCB-MNCs)

Other

Intra-articular injection of Cord Blood Mononuclear Cells (UCB-MNCs)

Primary outcomes

  1. Lysholm score

    Time frame: Compare the changes of 1 month, 3 months, 6 months and one year before treatment (baseline) and after (third injection)

    Evaluation of functional perception of daily activities and motor function levels of different intensities.The score ranges from 0 to 100 points, the lower the score, the more severe the knee joint damage.

  2. American knee society knee score

    Time frame: Compare the changes of 1 month, 3 months, 6 months and one year before treatment (baseline) and after (third injection)

    Evaluation of the overall function and shape of the knee joint.The score ranges from 0 to 100 points. The lower the score, the worse the knee joint function.

  3. the knee injury and osteoarthritis score

    Time frame: Compare the changes of 1 month, 3 months, 6 months and one year before treatment (baseline) and after (third injection)

    A questionnaire for evaluating the effectiveness of knee joint injury and osteoarthropathy treatment based on patient self-assessment management.The KOOS score consists of five parts, and each part contains a different number of questions. Each question has a minimum of 0 points and a maximum of 4 points. After the score of each part is calculated separately, it is converted into a percentile score through the conversion formula. A score of 0 in the converted percentile score means that the function of that part of the joint is extremely poor, and a score of 100 means that the function of this part of the joint is completely normal.

  4. Visual Analog Score for pain

    Time frame: Compare the changes of 1 month, 3 months, 6 months and one year before treatment (baseline) and after (third injection)

    Physicians Global Assessment to measure quality of life.The score ranges from 0 to 10 points, the lower the score, the more severe the pain.

Sponsors and collaborators

Lead sponsor

Lili Cao

Other

Registry information

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Aug 11, 2021
Registry last updated
Nov 8, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.